Arrowhead Pharmaceuticals

Quarterly Financials

Values in thousands2026-03-312025-12-312025-09-302025-06-30
Revenue
$73,737
$264,033
$256,472
$27,767
Gross Profit
73,737
264,033
256,472
27,767
EBITDA
-107,351
57,166
64,201
-148,484
EBIT
-113,719
50,776
57,815
-154,707
Net Income
-132,732
30,811
-23,750
-175,241
Net Change In Cash
73,737
264,033
256,472
27,767
Free Cash Flow
81,877
11,333
13,002
-157,084
Cash
188,517
201,643
226,548
129,793
Basic Shares
142,417
140,706
135,702
139,039

Annual Financials

Values in thousands2025-09-302024-09-302023-09-302022-09-30
Revenue
$829,448
$3,551
$240,735
$243,231
Gross Profit
829,448
-15,044
228,242
243,231
EBITDA
164,822
-561,513
-175,672
-168,086
EBIT
140,894
-580,108
-188,165
-178,507
Net Income
-1,631
-599,493
-205,275
-176,494
Net Change In Cash
829,448
3,551
240,735
243,231
Cost of Revenue
-76,362
Free Cash Flow
156,886
-604,320
-330,627
-188,908
Cash
226,548
102,685
110,891
108,005
Basic Shares
133,758
119,784
106,750
105,426

Earnings Calls

QuarterEPS
2026-03-31
-$0.93
2025-12-31
$0.22
2025-09-30
-$0.11
2025-06-30
-$1.26